Ryan J. Watts, the President and CEO of $DNLI, sold 35,198 shares of the company on 01-06-2026 for an estimated $580,767. We received data on the trade from a recent SEC filing. This was a sale of approximately 10.6% of their shares of this class of stock. Following this trade, they now own 296,833 shares of this class of $DNLI stock.
$DNLI Insider Trading Activity
$DNLI insiders have traded $DNLI stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $DNLI stock by insiders over the last 6 months:
- RYAN J. WATTS (President and CEO) sold 35,198 shares for an estimated $580,767
- ALEXANDER O. SCHUTH (COFO and Secretary) has made 0 purchases and 2 sales selling 20,155 shares for an estimated $323,981.
- CAROLE HO (Chief Medical Officer) has made 0 purchases and 2 sales selling 3,743 shares for an estimated $51,684.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DNLI Hedge Fund Activity
We have seen 125 institutional investors add shares of $DNLI stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 5,605,499 shares (-99.0%) from their portfolio in Q3 2025, for an estimated $81,391,845
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 4,667,797 shares (+74.5%) to their portfolio in Q3 2025, for an estimated $67,776,412
- HOLOCENE ADVISORS, LP added 2,732,540 shares (+677.8%) to their portfolio in Q3 2025, for an estimated $39,676,480
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,391,633 shares (+73.7%) to their portfolio in Q3 2025, for an estimated $34,726,511
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,013,927 shares (-30.6%) from their portfolio in Q3 2025, for an estimated $29,242,220
- FMR LLC removed 1,198,152 shares (-15.9%) from their portfolio in Q3 2025, for an estimated $17,397,167
- UBS GROUP AG added 1,061,589 shares (+111.7%) to their portfolio in Q3 2025, for an estimated $15,414,272
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DNLI Analyst Ratings
Wall Street analysts have issued reports on $DNLI in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Wedbush issued a "Outperform" rating on 12/05/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/08/2025
To track analyst ratings and price targets for $DNLI, check out Quiver Quantitative's $DNLI forecast page.
$DNLI Price Targets
Multiple analysts have issued price targets for $DNLI recently. We have seen 5 analysts offer price targets for $DNLI in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $25.0 on 01/07/2026
- Laura Chico from Wedbush set a target price of $30.0 on 12/11/2025
- Thomas Shrader from BTIG set a target price of $32.0 on 12/05/2025
- Jessica Fye from JP Morgan set a target price of $26.0 on 11/04/2025
- Matthew Harrison from Morgan Stanley set a target price of $30.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
